cmAngio® vs Aorta-CAD

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

cmAngio®

by CureMetrix

Aorta-CAD

by Imagen Technologies

AI Verdict

cmAngio® is designed for detecting Breast Arterial Calcifications on mammograms, offering insights into women's cardiovascular health. In contrast, Aorta-CAD focuses on identifying signs of Aortic Atherosclerosis and Ectasia on chest X-rays to assist in general cardiovascular diagnostics. While both are FDA-cleared AI tools for cardiovascular risk assessment in radiology, their distinct target conditions and imaging modalities make them suitable for different clinical applications.

Choose cmAngio® if…

Choose cmAngio® if your clinical focus is leveraging existing mammography screenings to provide additional cardiovascular risk insights for women. This tool is ideal for practices seeking to identify Breast Arterial Calcifications (BAC) to aid in early cardiovascular health assessment without requiring additional radiation or procedures, integrating seamlessly into breast imaging workflows.

View cmAngio® →

Choose Aorta-CAD if…

Choose Aorta-CAD if your practice frequently utilizes chest X-rays and aims to enhance the detection of Aortic Atherosclerosis and Aortic Ectasia across a broad patient population. This cloud-based AI solution is best suited for improving the accuracy and immediacy of identifying significant aortic conditions during routine chest imaging, assisting both radiologists and PCPs in their diagnostic interpretations.

View Aorta-CAD →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	cmAngio®	Aorta-CAD
Pricing	Paid, out-of-pocket	Unknown
Deployment	Cloud-based, integrates with any DICOM-compliant viewer	Cloud-based software that integrates into existing chest X-ray workflows and Picture Archiving and Communication System (PACS) viewers.
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	cmAngio®	Aorta-CAD
Tool Name	cmAngiou00ae	Aorta-CAD
Company	CureMetrix	Imagen Technologies
Primary Detection Focus	Breast Arterial Calcifications (BAC) on mammograms	Aortic Atherosclerosis and Aortic Ectasia on chest X-rays
Key Feature 1	AI-based detection of Breast Arterial Calcifications (BAC)	Detects and highlights radiographic findings suggestive of Aortic Atherosclerosis and Aortic Ectasia
Key Feature 2	Processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams	Cloud-based, software-only medical device
Key Feature 3	Provides visualization of BAC location on a scorecard	Utilizes deep learning algorithms for analysis

Videos

Demos, reviews, and walkthroughs featuring cmAngio® and Aorta-CAD.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What specific cardiovascular conditions do these AI tools help detect, and on which imaging modalities?

cmAngiou00ae by CureMetrix is designed to detect Breast Arterial Calcifications (BAC) on Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams. Aorta-CAD by Imagen Technologies assists in detecting signs of Aortic Atherosclerosis and Aortic Ectasia on chest X-rays.

Which medical specialties are these AI solutions primarily designed to support?

cmAngiou00ae is primarily relevant for Cardiology, Obstetrics & Gynecology, and Radiology, offering insights into women's cardiovascular health from mammograms. Aorta-CAD mainly serves Cardiology, Internal Medicine, and Radiology by analyzing chest X-rays for aortic conditions.

What are the key differences in the type of findings or visualizations provided by each tool?

cmAngiou00ae provides visualization of BAC location on a scorecard and enables BAC identification and reporting without additional radiation or procedures. Aorta-CAD detects and highlights radiographic findings suggestive of Aortic Atherosclerosis and Aortic Ectasia, creating annotations via an overlay that can be toggled on/off.

Are there any reported clinical performance metrics or study results available for these tools?

Aorta-CAD has demonstrated a 62% relative reduction in misses for aortic calcification and a 35% relative reduction in misses for dilated aorta in a clinical study. cmAngiou00ae has shown high performance for BAC detection on digital mammography with an AUC of 0.98, sensitivity of 94%, and specificity of 96% in a study.

How do these tools address data security and compliance, specifically regarding Business Associate Agreements (BAAs)?

Both cmAngiou00ae and Aorta-CAD are HIPAA-compliant. For cmAngiou00ae, physicians need to contact the vendor for Business Associate Agreement (BAA) details, whereas Aorta-CAD explicitly states it has a BAA.

Can these tools be customized to meet specific clinical goals or preferences?

cmAngiou00ae offers an adjustable operating point to meet clinical goals. The provided information for Aorta-CAD does not explicitly mention customizable operating points, but it does integrate seamlessly into existing workflows.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring cmAngio® or Aorta-CAD

Backers

Who funded each tool's parent company.

cmAngio®

Keshif Ventures